All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, August 19, 2022
Home » Blogs » BioWorld Perspectives » Reason Free from Passion? That’s Not Biotech

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

Reason Free from Passion? That’s Not Biotech

Oct. 27, 2011
By Jennifer Boggs
No Comments

SAN FRANCISCO ‑ At this week’s BIO Investor Forum in San Francisco, there was talk of how the biotech industry has squandered money, paying for infrastructure when it should have been paying only for development and continuing to fund programs even when the early data weren’t stellar.

I admit it is frustrating to write about companies that are launching yet another Phase III study, because they claim their drug’s “really going to work this time.” And the skyrocketing drug development costs are one reason my fellow Americans and I are paying a fortune every month for health care.

During a Tuesday plenary session, some even asked why biotech can’t operate as efficiently as the technology sector, where seemingly bad ideas are scrapped before they can gain too much financial traction. That doesn’t sound like a bad idea, right? Let’s turn drug development into a factory-like process: advance programs quickly and kill the ones that don’t immediately perform.

In other words, take the go-no go decision out of the hands of the people who invented the drug or the people whose jobs are tied to its success. Create a dispassionate drug development process.

But as BIO’s John Craighead noted, “’dispassionate’ is not a very good word for this industry in general,” and I would have to agree.

Biotech has been built on the backs of scientists working long hours and executives who sometimes seem to champion a drug through the development process by sheer will alone, convincing investors to take a risk on a new – and therefore risky – invention. And more than one biotech has relied on funding from its own founders either to establish the firm or keep it afloat during tough times.

Yes, at the end of the day, the data are what counts. But to get to that data, sometimes there needs to be an extra little push along the way. Because innovation has never been easy.

And this isn’t the technology industry. Biotech isn’t obsessed with making cell phones that can communicate with Mars or a laptop that can fit inside your pocket. Biotech is working on medications that could improve lives or extend lives, possibly even save lives.

So maybe it’s all right to get a little passionate now and then.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Aug. 19, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Aug. 19, 2022.
  • Pig organ cells

    Whole body cellular function recovery in pigs after death

    Science
    A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...
  • TPOXX

    Siga leads monkeypox antiviral research, amid lack of interest from big pharma

    BioWorld
    After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing